Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404388 | 1.00 | KMT2A (0.58) | KMT2ATDP1DRD2ADRA1DADRA1A | |
| SCHEMBL2404226 | 1.00 | KMT2A (0.58) | KMT2ATDP1DRD2ADRA1DADRA1A | |
| SCHEMBL2400473 | 0.91 | CNR1 (0.47) | KMT2ATDP1MEN1MAPTMMP2 | |
| SCHEMBL2404113 | 0.91 | CNR1 (0.47) | KMT2ATDP1MEN1MAPTMMP2 | |
| SCHEMBL2400476 | 0.91 | CNR1 (0.47) | KMT2ATDP1MEN1MAPTMMP2 | |
| SCHEMBL2404245 | 0.89 | KMT2A (0.42) | KMT2ATDP1DRD2ADRA1DADRA1A | |
| SCHEMBL2402005 | 0.89 | KMT2A (0.42) | KMT2ATDP1DRD2ADRA1DADRA1A | |
| SCHEMBL2402008 | 0.89 | KMT2A (0.42) | KMT2ATDP1DRD2ADRA1DADRA1A | |
| SCHEMBL2402257 | 0.88 | KMT2A (0.44) | KMT2ATDP1DRD2ADRA1DADRA1A | |
| SCHEMBL2402253 | 0.88 | KMT2A (0.44) | KMT2ATDP1DRD2ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017773-B2 | Cyclohexyl sulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1979322-B1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20100120791-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | disclosed |
| EP-1979322-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007082840-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173511-A1 | Cyclohexyl sulfonamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120791-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES | HRH3, HRH4, HRH1 | KMT2A 338/4885TDP1 4241/4885DRD2 1307/4885 |
| US-20070173511-A1 | Cyclohexyl sulfonamide derivatives | HRH3, HRH4, HRH1 | KMT2A 338/4885TDP1 4241/4885DRD2 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.